-
From 3 fixed-point production pilots to 57 information monitoring: the history of changes in drug shortage intervention management
Time of Update: 2021-12-03
The actual increase, and taking into consideration the wishes of the desacetyl-lanoside injection manufacturers, the above-mentioned two varieties will no longer be subject to fixed-point production, and they will be included in the key monitoring scope of shortage drugs; methimazole tablets (5mg), lobe hydrochloride Lin injection (1ml: 3mg) will continue to implement the pilot project of designated production for one year .
-
Merck's new crown oral drug effective rate drops to 30%
Time of Update: 2021-12-03
On November 26, Merck and Ridgeback announced updated clinical data for the new crown oral drug Molnupiravir for the treatment of mild to moderate new crowns .
In the interim analysis, Molnupiravir reduced the risk of hospitalization or death by approximately 50% ; on the 29th day after randomization, 7.
-
Recently, two more domestically-made innovative drugs have been approved for marketing!
Time of Update: 2021-12-03
They are aoribatinib tablets for the treatment of resistance to any tyrosine kinase inhibitor; innovative PD-L1 antibody drugs, suitable for unresectable or metastatic microsatellite highly unstable (MSI-H) or mismatch repair Envolimab injection for the treatment of adult patients with advanced solid tumors with genetic defects (dMMR) .
-
Medical representatives face new challenges!
Time of Update: 2021-12-03
From 2022 to 2024, the task of reforming the DRG/DIP payment method will be fully completed, and the high-quality development of medical insurance will be promoted .
-
Section 6!
Time of Update: 2021-12-03
WenSunshineOn November 26, the official website of the Food and Drug Administration showed that Bevacizumab biosimilar (MIL60) of Betta Pharmaceuticals was approved for marketing for the treatment of advanced, metastatic or recurrent non-small cell lung cancer and metastatic colorectal Cancer patients .
-
Shi Fuxin is the head of the new drug discovery and preclinical research of Ruizheng and the general manager of the U.S. subsidiary
Time of Update: 2021-12-03
Shi Fuxin will lead the research team to be responsible for innovative technology development, new target confirmation and product pipeline layout, and to quickly advance the product projects developed in the early stage into the clinic .
-
The overall growth rate of the chemical preparation industry has improved, and focus on this type of enterprise
Time of Update: 2021-12-03
In recent years, with China's significant increase in public medical investment, as well as the steady economic growth, the improvement of people's living standards, and the enhancement of health awareness, the domestic chemical pharmaceutical preparation market has maintained rapid growth .
-
New crown Nu strain appeared in the arena
Time of Update: 2021-12-03
Drug source analysisDrug source analysisViruses mutate all the time, so the emergence of new strains is always happening .
This not only makes the control of the new crown in low-income countries stretched, but also increases the chance that Nu, a highly variable strain, will inevitably spread globally .
-
Right Biao Yangtze River!
Time of Update: 2021-12-03
com database A few days ago, the CDE official website showed that Sichuan Guorui Pharmaceutical's dexmedetomidine hydrochloride sodium chloride injection and dexmedetomidine hydrochloride injection have been accepted as imitation 3 types of listing applications .
-
6 pharmacies will be available soon
Time of Update: 2021-12-03
It is worth mentioning that this wave of chain pharmacies getting listed on the market represents two trends: one professional development (Sipai Health, Yuanxin Technology, Dajia Weikang), focusing on the new pattern of prescription outflow; and an innovative development (Dingdong Kuaiyao , Quanyuantang), focusing on the new trend of Internet medicine .
-
The pharmaceutical equipment industry has a strong momentum of development, and companies should keep pace with the times and accelerate innovation
Time of Update: 2021-12-03
In general, in the context of many favorable pharmaceutical policies and the continuous development of science and technology, the industry expects that China's pharmaceutical equipment industry will usher in more opportunities, but at the same time, the competition of related enterprises will also reach new heights.
-
Insulin enters the sixth batch of drug collection, diabetic patients may bid farewell to the "sweet burden"
Time of Update: 2021-12-03
In addition, an analyst in the pharmaceutical industry said that due to the large base of diabetes patients and insulin is an important drug for diabetes treatment, which involves people’s livelihood issues, the country has an incentive to reduce the cost of medication.
-
2022 The 9th International Biological Fermentation Products and Technology Equipment Exhibition (Jinan)
Time of Update: 2021-12-03
March 30-April 1, 2022 | Shandong International Convention and Exhibition Center (No. 1 Rizhao Road, Jinan) 4 exhibition linkage, 600+ brands, sharing 36000+ buyers, 40000㎡ exhibition area Supporting
-
Pharmaceutical equipment is continuously helping the Chinese medicine industry to accelerate its development in the direction of modernization
Time of Update: 2021-12-03
In general, it is the responsibility of pharmaceutical equipment companies to use modern science and technology to promote the modernization of Chinese medicine and to open up new paths for the inheritance, innovation and development of Chinese medicine.
-
How will the pharmaceutical equipment market be interpreted at the end of the year, and how will it be laid out in the next phase?
Time of Update: 2021-12-03
It is expected that the market for pharmaceutical equipment at the end of the year will still be worth seeing in the context of the continued prosperity of the innovative medicine and CXO industries .
-
As the market continues to expand, the pharmaceutical machinery industry will accelerate development in these directions
Time of Update: 2021-12-03
In this regard, the industry believes that under this trend, through the continuous development and innovation of pharmaceutical machinery companies in the future, domestic pharmaceutical equipment companies will gradually become a segment of China's high-end manufacturing, and their performance will continue to grow; in addition, the industry will also The cyclical attribute is gradually faded to usher in long-term growth .
-
The results of insulin production in China are released!
Time of Update: 2021-12-03
This collection covers the second- and third-generation insulins commonly used in clinical practice, involving 11 companies and 16 generic varieties, and the average price of the products to be selected is reduced by 48 %, it is estimated that 9 billion yuan can be saved every year, which will bring good news to over 140 million diabetic patients in China .
-
NMPA approves the listing of Xuanqijian Bone Tablets, Qizhi Yishen Capsules and Kunxinning Granules
Time of Update: 2021-12-03
Recently, the National Medical Products Administration approved the marketing registration application for three innovative Chinese medicines: Xuanqijiangu Pian, Qizhi Yishen Capsule and Kunxinning Granules .
Recently, the National Medical Products Administration approved the marketing registration application for three innovative Chinese medicines: Xuanqijiangu Pian, Qizhi Yishen Capsule and Kunxinning Granules .
-
The prospects for the development of Chinese medicine overseas markets are considerable, and these bottlenecks still need to be broken
Time of Update: 2021-12-03
Therefore, if pharmaceutical companies want to better guarantee drug safety, they must use technological innovation to develop modern Chinese medicine scientific research and industrial production technology to continuously promote the development of the Chinese medicine industry in a high-quality direction .
-
Health Commission: 21 new confirmed cases of 41 local cases on the 28th
Time of Update: 2021-12-02
As of 24:00 on November 28, according to reports from 31 provinces (autonomous regions and municipalities) and the Xinjiang Production and Construction Corps, there are currently 787 confirmed cases (including 8 severe cases), a total of 93,249 cured and discharged cases, and a total of 4,636 deaths.
